Biotech Values

[caravon]

Is Stimuvax dead in NSCLC? It is a good question.

Is ArQule's Tiva dead for NSCLC? Apparently, the answer is Yes if one intend to treat the entire NSCLC patient population. Tarceva and Irissa do not work for all NSCLC patients either.

It appears that NSCLC is not a single disease but rather an array of various things. Furthermore, these things do change as the NSCLC disease progresses and various mutation processes take place.

Unfortunately, until now, researchers were trying to find a magic bullet capable of addressing and solving all NSCLC problems.

I would like to suggest that we shall wait for the results before making the final decision regarding to Stimuvax in NSCLC.

Finally, I see nothing wrong "with data mining" as long as these data analysis are done on solid scientific bases.